Cargando…

Safety and Effectiveness of Blonanserin in Chinese Patients with Schizophrenia: An Interim Analysis of a 12-Week Open-Label Prospective Multi-Center Post-marketing Surveillance

Schizophrenia is an unexplained, complex and serious mental illness. Blonanserin (BNS) is a new antipsychotic drug widely used in the treatment of schizophrenia. However, large-scale clinical studies have not been conducted in China. A multi-center, prospective, open-label, 12-week surveillance was...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Haishan, Wang, Xijin, Liu, Xuejun, Sang, Hong, Bo, Qijing, Yang, Xiaodong, Xun, Zhiyuan, Li, Keqing, Zhang, Ruiling, Sun, Meijuan, Cai, Duanfang, Deng, Huaili, Zhao, Guijun, Li, Juhong, Liu, Xianglai, Zhan, Guilai, Chen, Jindong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9435526/
https://www.ncbi.nlm.nih.gov/pubmed/36061293
http://dx.doi.org/10.3389/fpsyt.2022.935769
_version_ 1784781161778642944
author Wu, Haishan
Wang, Xijin
Liu, Xuejun
Sang, Hong
Bo, Qijing
Yang, Xiaodong
Xun, Zhiyuan
Li, Keqing
Zhang, Ruiling
Sun, Meijuan
Cai, Duanfang
Deng, Huaili
Zhao, Guijun
Li, Juhong
Liu, Xianglai
Zhan, Guilai
Chen, Jindong
author_facet Wu, Haishan
Wang, Xijin
Liu, Xuejun
Sang, Hong
Bo, Qijing
Yang, Xiaodong
Xun, Zhiyuan
Li, Keqing
Zhang, Ruiling
Sun, Meijuan
Cai, Duanfang
Deng, Huaili
Zhao, Guijun
Li, Juhong
Liu, Xianglai
Zhan, Guilai
Chen, Jindong
author_sort Wu, Haishan
collection PubMed
description Schizophrenia is an unexplained, complex and serious mental illness. Blonanserin (BNS) is a new antipsychotic drug widely used in the treatment of schizophrenia. However, large-scale clinical studies have not been conducted in China. A multi-center, prospective, open-label, 12-week surveillance was carried out to evaluate the safety and effectiveness of BNS in patients with schizophrenia in China. Safety assessments included adverse drug reactions (ADRs), extrapyramidal symptoms (EPS), akathisia, concomitant medications for EPS by the end of treatment, and the changes in body weight from baseline by the end of treatment. The effectiveness was evaluated by the Brief Psychiatric Rating Scale (BPRS). From September 2018 to May 2020, of the 1,060 patients enrolled, 1,018 were included in the full analysis set (FAS) and safety set (SS), respectively. ADRs were developed in 205 patients among the included, the incidence being 20.1%. ADRs of EPS occurred in 169 patients, the incidence being 16.6%, ADRs of akathisia occurred in 90 patients, the incidence being 8.8%; concomitant therapeutic and prophylactic agents for EPS accounts for 19.2%; 4.0% of patients had a ≥7% increase in body weight from baseline at 12 weeks after initiating treatment. Using the last-observation-carried-forward (LOCF) method, the changes in total BPRS scores were −11.2 ± 10.17 (N = 1,018), −16.8 ± 12.69 (N = 1,018) and −20.6 ± 13.99 (N = 1,018) after 2/4, 6/8, or 12 weeks, respectively. 53.5% (545/1,018) patients showed response to blonanserin treatment in week 12. The post-marketing surveillance results of BNS demonstrates safety profile and effectiveness of the drug.
format Online
Article
Text
id pubmed-9435526
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94355262022-09-02 Safety and Effectiveness of Blonanserin in Chinese Patients with Schizophrenia: An Interim Analysis of a 12-Week Open-Label Prospective Multi-Center Post-marketing Surveillance Wu, Haishan Wang, Xijin Liu, Xuejun Sang, Hong Bo, Qijing Yang, Xiaodong Xun, Zhiyuan Li, Keqing Zhang, Ruiling Sun, Meijuan Cai, Duanfang Deng, Huaili Zhao, Guijun Li, Juhong Liu, Xianglai Zhan, Guilai Chen, Jindong Front Psychiatry Psychiatry Schizophrenia is an unexplained, complex and serious mental illness. Blonanserin (BNS) is a new antipsychotic drug widely used in the treatment of schizophrenia. However, large-scale clinical studies have not been conducted in China. A multi-center, prospective, open-label, 12-week surveillance was carried out to evaluate the safety and effectiveness of BNS in patients with schizophrenia in China. Safety assessments included adverse drug reactions (ADRs), extrapyramidal symptoms (EPS), akathisia, concomitant medications for EPS by the end of treatment, and the changes in body weight from baseline by the end of treatment. The effectiveness was evaluated by the Brief Psychiatric Rating Scale (BPRS). From September 2018 to May 2020, of the 1,060 patients enrolled, 1,018 were included in the full analysis set (FAS) and safety set (SS), respectively. ADRs were developed in 205 patients among the included, the incidence being 20.1%. ADRs of EPS occurred in 169 patients, the incidence being 16.6%, ADRs of akathisia occurred in 90 patients, the incidence being 8.8%; concomitant therapeutic and prophylactic agents for EPS accounts for 19.2%; 4.0% of patients had a ≥7% increase in body weight from baseline at 12 weeks after initiating treatment. Using the last-observation-carried-forward (LOCF) method, the changes in total BPRS scores were −11.2 ± 10.17 (N = 1,018), −16.8 ± 12.69 (N = 1,018) and −20.6 ± 13.99 (N = 1,018) after 2/4, 6/8, or 12 weeks, respectively. 53.5% (545/1,018) patients showed response to blonanserin treatment in week 12. The post-marketing surveillance results of BNS demonstrates safety profile and effectiveness of the drug. Frontiers Media S.A. 2022-08-18 /pmc/articles/PMC9435526/ /pubmed/36061293 http://dx.doi.org/10.3389/fpsyt.2022.935769 Text en Copyright © 2022 Wu, Wang, Liu, Sang, Bo, Yang, Xun, Li, Zhang, Sun, Cai, Deng, Zhao, Li, Liu, Zhan and Chen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Psychiatry
Wu, Haishan
Wang, Xijin
Liu, Xuejun
Sang, Hong
Bo, Qijing
Yang, Xiaodong
Xun, Zhiyuan
Li, Keqing
Zhang, Ruiling
Sun, Meijuan
Cai, Duanfang
Deng, Huaili
Zhao, Guijun
Li, Juhong
Liu, Xianglai
Zhan, Guilai
Chen, Jindong
Safety and Effectiveness of Blonanserin in Chinese Patients with Schizophrenia: An Interim Analysis of a 12-Week Open-Label Prospective Multi-Center Post-marketing Surveillance
title Safety and Effectiveness of Blonanserin in Chinese Patients with Schizophrenia: An Interim Analysis of a 12-Week Open-Label Prospective Multi-Center Post-marketing Surveillance
title_full Safety and Effectiveness of Blonanserin in Chinese Patients with Schizophrenia: An Interim Analysis of a 12-Week Open-Label Prospective Multi-Center Post-marketing Surveillance
title_fullStr Safety and Effectiveness of Blonanserin in Chinese Patients with Schizophrenia: An Interim Analysis of a 12-Week Open-Label Prospective Multi-Center Post-marketing Surveillance
title_full_unstemmed Safety and Effectiveness of Blonanserin in Chinese Patients with Schizophrenia: An Interim Analysis of a 12-Week Open-Label Prospective Multi-Center Post-marketing Surveillance
title_short Safety and Effectiveness of Blonanserin in Chinese Patients with Schizophrenia: An Interim Analysis of a 12-Week Open-Label Prospective Multi-Center Post-marketing Surveillance
title_sort safety and effectiveness of blonanserin in chinese patients with schizophrenia: an interim analysis of a 12-week open-label prospective multi-center post-marketing surveillance
topic Psychiatry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9435526/
https://www.ncbi.nlm.nih.gov/pubmed/36061293
http://dx.doi.org/10.3389/fpsyt.2022.935769
work_keys_str_mv AT wuhaishan safetyandeffectivenessofblonanserininchinesepatientswithschizophreniaaninterimanalysisofa12weekopenlabelprospectivemulticenterpostmarketingsurveillance
AT wangxijin safetyandeffectivenessofblonanserininchinesepatientswithschizophreniaaninterimanalysisofa12weekopenlabelprospectivemulticenterpostmarketingsurveillance
AT liuxuejun safetyandeffectivenessofblonanserininchinesepatientswithschizophreniaaninterimanalysisofa12weekopenlabelprospectivemulticenterpostmarketingsurveillance
AT sanghong safetyandeffectivenessofblonanserininchinesepatientswithschizophreniaaninterimanalysisofa12weekopenlabelprospectivemulticenterpostmarketingsurveillance
AT boqijing safetyandeffectivenessofblonanserininchinesepatientswithschizophreniaaninterimanalysisofa12weekopenlabelprospectivemulticenterpostmarketingsurveillance
AT yangxiaodong safetyandeffectivenessofblonanserininchinesepatientswithschizophreniaaninterimanalysisofa12weekopenlabelprospectivemulticenterpostmarketingsurveillance
AT xunzhiyuan safetyandeffectivenessofblonanserininchinesepatientswithschizophreniaaninterimanalysisofa12weekopenlabelprospectivemulticenterpostmarketingsurveillance
AT likeqing safetyandeffectivenessofblonanserininchinesepatientswithschizophreniaaninterimanalysisofa12weekopenlabelprospectivemulticenterpostmarketingsurveillance
AT zhangruiling safetyandeffectivenessofblonanserininchinesepatientswithschizophreniaaninterimanalysisofa12weekopenlabelprospectivemulticenterpostmarketingsurveillance
AT sunmeijuan safetyandeffectivenessofblonanserininchinesepatientswithschizophreniaaninterimanalysisofa12weekopenlabelprospectivemulticenterpostmarketingsurveillance
AT caiduanfang safetyandeffectivenessofblonanserininchinesepatientswithschizophreniaaninterimanalysisofa12weekopenlabelprospectivemulticenterpostmarketingsurveillance
AT denghuaili safetyandeffectivenessofblonanserininchinesepatientswithschizophreniaaninterimanalysisofa12weekopenlabelprospectivemulticenterpostmarketingsurveillance
AT zhaoguijun safetyandeffectivenessofblonanserininchinesepatientswithschizophreniaaninterimanalysisofa12weekopenlabelprospectivemulticenterpostmarketingsurveillance
AT lijuhong safetyandeffectivenessofblonanserininchinesepatientswithschizophreniaaninterimanalysisofa12weekopenlabelprospectivemulticenterpostmarketingsurveillance
AT liuxianglai safetyandeffectivenessofblonanserininchinesepatientswithschizophreniaaninterimanalysisofa12weekopenlabelprospectivemulticenterpostmarketingsurveillance
AT zhanguilai safetyandeffectivenessofblonanserininchinesepatientswithschizophreniaaninterimanalysisofa12weekopenlabelprospectivemulticenterpostmarketingsurveillance
AT chenjindong safetyandeffectivenessofblonanserininchinesepatientswithschizophreniaaninterimanalysisofa12weekopenlabelprospectivemulticenterpostmarketingsurveillance